EA201500064A1 - Активаторы ampk и их применение в терапевтических целях - Google Patents

Активаторы ampk и их применение в терапевтических целях

Info

Publication number
EA201500064A1
EA201500064A1 EA201500064A EA201500064A EA201500064A1 EA 201500064 A1 EA201500064 A1 EA 201500064A1 EA 201500064 A EA201500064 A EA 201500064A EA 201500064 A EA201500064 A EA 201500064A EA 201500064 A1 EA201500064 A1 EA 201500064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver disease
application
ampk
therapeutic purposes
compounds
Prior art date
Application number
EA201500064A
Other languages
English (en)
Other versions
EA026300B1 (ru
Inventor
Даниель Краво
Софи Халлаку-Бозек
Себастьен Больз
Франк Лёпифр
Лоран Фаверьель
Жан-Дени Дюран
Кристин Шарон
Original Assignee
Поксел
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Поксел filed Critical Поксел
Publication of EA201500064A1 publication Critical patent/EA201500064A1/ru
Publication of EA026300B1 publication Critical patent/EA026300B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение имеет отношение к соединениям, которые являются непосредственными активаторами AMPK (АМР-активированной протеинкиназы), и их применению при лечении нарушений, регулируемых активацией AMPK. Например, соединения согласно изобретению используются при лечении диабета, метаболического синдрома, ожирения, заболевания печени, жировой дистрофии печени, неалкогольной жировой дистрофии печени (NAFLD), неалкогольного стеатогепатита (NASH), фиброза печени, дислипидемии, гипертриглицеридемии, гиперхолестеринемии, воспаления, рака, сердечно-сосудистых заболеваний, атеросклероза, высокого кровяного давления, ретинопатии или невропатии.
EA201500064A 2012-06-29 2013-06-28 Активаторы ampk и их применение в терапевтических целях EA026300B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305775.4A EP2679591A1 (en) 2012-06-29 2012-06-29 Thienopyridone derivatives useful as activators of AMPK
PCT/EP2013/063741 WO2014001554A1 (en) 2012-06-29 2013-06-28 Thienopyridone derivatives useful as activators of ampk

Publications (2)

Publication Number Publication Date
EA201500064A1 true EA201500064A1 (ru) 2015-08-31
EA026300B1 EA026300B1 (ru) 2017-03-31

Family

ID=48703549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500064A EA026300B1 (ru) 2012-06-29 2013-06-28 Активаторы ampk и их применение в терапевтических целях

Country Status (26)

Country Link
US (1) US9284329B2 (ru)
EP (2) EP2679591A1 (ru)
JP (1) JP5972460B2 (ru)
KR (1) KR101704448B1 (ru)
CN (2) CN104395319B (ru)
AU (1) AU2013283239B2 (ru)
BR (1) BR112014032526B1 (ru)
CA (1) CA2876789C (ru)
CY (1) CY1118213T1 (ru)
DK (1) DK2867240T3 (ru)
EA (1) EA026300B1 (ru)
ES (1) ES2603737T3 (ru)
HR (1) HRP20161482T1 (ru)
HU (1) HUE030946T2 (ru)
IL (1) IL236221A (ru)
IN (1) IN2014MN02661A (ru)
LT (1) LT2867240T (ru)
ME (1) ME02537B (ru)
MX (1) MX359221B (ru)
PL (1) PL2867240T3 (ru)
PT (1) PT2867240T (ru)
RS (1) RS55308B1 (ru)
SI (1) SI2867240T1 (ru)
SM (1) SMT201600418B (ru)
WO (1) WO2014001554A1 (ru)
ZA (1) ZA201500593B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105078992B (zh) * 2014-05-23 2017-11-21 资元堂生物科技股份有限公司 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910129A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104910130A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
KR101925020B1 (ko) 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
US11840527B2 (en) * 2018-02-08 2023-12-12 Enyo Pharma Non-fused thiophene derivatives and their uses
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
WO2020099678A1 (en) * 2018-11-16 2020-05-22 Poxel Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2020215034A1 (en) * 2019-04-19 2020-10-22 The Regents Of The University Of California An ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2021037702A1 (en) 2019-08-28 2021-03-04 Poxel Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
JP2023503279A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ジベンゾピランａｍｐｋ活性化剤化合物、組成物、方法、及びその使用
AU2021244824A1 (en) * 2020-03-26 2022-10-27 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
WO2021198284A1 (en) 2020-03-30 2021-10-07 Poxel Use of a thienopyridone derivative in the treatment of cardiovascular diseases
US20230149370A1 (en) 2020-03-30 2023-05-18 Poxel Use of a thienopyridone derivative in the treatment of diabetic nephropathy
MX2022012350A (es) 2020-04-02 2022-10-27 Poxel Uso de un derivado de tienopiridona en el tratamiento de poliquistosis renal autosomica dominante (adpkd).
WO2021204751A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
KR101630466B1 (ko) 2008-04-11 2016-06-14 메르크 파텐트 게엠베하 Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체
SI2280952T1 (sl) 2008-05-05 2012-09-28 Merck Patent Gmbh Derivati tienopiridona kot aktivatorji AMP-aktivirane protein kinaze (AMPK)

Also Published As

Publication number Publication date
EP2679591A1 (en) 2014-01-01
MX359221B (es) 2018-09-18
IL236221A0 (en) 2015-02-01
CN107266467A (zh) 2017-10-20
IN2014MN02661A (ru) 2015-08-28
RS55308B1 (sr) 2017-03-31
EP2867240A1 (en) 2015-05-06
CA2876789C (en) 2017-01-31
ZA201500593B (en) 2016-01-27
IL236221A (en) 2017-12-31
DK2867240T3 (en) 2016-12-05
JP2015521651A (ja) 2015-07-30
HUE030946T2 (en) 2017-06-28
WO2014001554A1 (en) 2014-01-03
KR101704448B1 (ko) 2017-02-08
BR112014032526A2 (pt) 2017-06-27
KR20150033709A (ko) 2015-04-01
AU2013283239A1 (en) 2015-01-22
JP5972460B2 (ja) 2016-08-17
AU2013283239B2 (en) 2016-01-28
CN104395319B (zh) 2017-10-27
US20150166566A1 (en) 2015-06-18
EA026300B1 (ru) 2017-03-31
CN104395319A (zh) 2015-03-04
BR112014032526B1 (pt) 2022-11-01
CY1118213T1 (el) 2017-06-28
EP2867240B1 (en) 2016-09-14
PL2867240T3 (pl) 2017-02-28
CA2876789A1 (en) 2014-01-03
SI2867240T1 (sl) 2017-01-31
ES2603737T3 (es) 2017-03-01
MX2014016107A (es) 2015-11-16
HRP20161482T1 (hr) 2016-12-30
LT2867240T (lt) 2016-12-27
PT2867240T (pt) 2016-11-24
ME02537B (me) 2017-02-20
US9284329B2 (en) 2016-03-15
SMT201600418B (it) 2017-01-10

Similar Documents

Publication Publication Date Title
EA201500064A1 (ru) Активаторы ampk и их применение в терапевтических целях
PH12020550216A1 (en) Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
CY1120996T1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
WO2014168548A8 (en) Therapeutic delivery vesicles
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
TW201129382A (en) Antibody formulation and therapeutic regimens
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
PH12015502108A1 (en) Pharmaceutical combination drug
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM